Navigation Links
Pharmasset Appoints Herbert J. Conrad as a Director
Date:3/27/2008

PRINCETON, N.J., March 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is pleased to announce the appointment of Herbert J. Conrad as a member of the Board of Directors and the Nominating and Corporate Governance Committee. Mr. Conrad is currently the Chairman of the Board of Directors of Sapphire Therapeutics, a Director of Savient Pharmaceuticals, Celldex and Symphony Evolution, and serves on the Medical Advisory Board of Henry Schein. From 1960 to 1993, Mr. Conrad served in a variety of marketing and strategic planning roles at Hoffmann LaRoche, and he was the President of the Roche Pharmaceuticals Division and a Member of the Executive Committee and Board of Directors from 1982 through 1993. Mr. Conrad has been involved in a number of business, industry, academic, civic and philanthropic organizations, and he also served in the U.S. Army's Medical Services Corps. Mr. Conrad earned his undergraduate and graduate degrees in Pharmacy from the Brooklyn College of Pharmacy. He also has received a Doctorate in Humane Letters (Honorary) from Long Island University.

"Pharmasset is honored to welcome Herb Conrad to our Board of Directors," stated G. Steven Burrill, CEO of Burrill & Company and Pharmasset's Chairman of the Board of Directors. "Herb has tremendous pharmaceutical industry experience, and we will benefit enormously from his guidance as Pharmasset continues its growth and evolution."

About Pharmasset

Pharmasset is a pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the developme
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... XIFIN Inc., the leading provider of revenue ... that XIFIN,s CEO and Executive Chairman, Lale ... College Conference in New Orleans on April ... executives, laboratory administrators and pathologists from many ...
... friendlyHOUSTON, April 14 US Oncology, Inc., supporting the nation,s ... Web site, usoncology.com . In order to ... usoncology.com is part of a new branding effort ... aspect of cancer care. , , For the ...
... field of medical microbiology, biodefense and pathogens to febit, ... and HEIDELBERG, Germany, April 14 febit ... Ph.D., for its Scientific Advisory Board. Dr. Keim ... Division at TGen (The Translational ...
Cached Biology Technology:XIFIN Inc. CEO to Speak at Executive War College Conference 2XIFIN Inc. CEO to Speak at Executive War College Conference 3US Oncology Launches New Web Site 2US Oncology Launches New Web Site 3US Oncology Launches New Web Site 4US Oncology Launches New Web Site 5US Oncology Launches New Web Site 6Paul Keim Appointed to febit's Scientific Advisory Board 2
(Date:10/25/2014)... 22, 2014 This report covers the specifics ... space in heavy pursuit of research due to its ... compared to other RNA components. miRNA,s non-coding nature and ... candidate for use as a biomarker for a variety ... and diagnostics for the advancement in therapeutic development. Furthermore ...
(Date:10/22/2014)... -- Leading identity analyst firm Acuity Market Intelligence forecasts that ... will have a chip-based National eID card, including near-complete ... Asia , with its vast population, is ... 60% of all National eID cards issued between 2014 ... National eID Industry Report: 2014 Edition" — ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... sea ice in the Arctic has shrunk to its ... 30 years ago, opening up the Northwest Passage ... has been historically impassable. In the mosaic image ... September 2007 by the Advanced Synthetic Aperture Radar (ASAR) ...
... 2007 American Society for Microbiology (ASM) sanofi-aventis U.S. ... M.D., Ph.D., Chief, Laboratory of Malaria and Vector ... Bethesda, Maryland. Supported by an unrestricted grant ... in antimicrobial chemotherapy. Dr. Wellems has had ...
... and volunteers who helped in the clean-up effort after ... of Spain exhibit prolonged respiratory symptoms resulting from their ... to examine the long-term effects of such exposures on ... reported in the second issue for September of the ...
Cached Biology News:Satellites witness lowest Arctic ice coverage in history 2Prolonged respiratory problems for oil spill clean-up volunteers 2Prolonged respiratory problems for oil spill clean-up volunteers 3
Reacts with the 80 kDa fragment of the M-chain of human merosin....
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: